Maria R. Baer

This paper shows that STING agonists combined with epigenetic drugs enhance necroptosis in TP53-mutated AML by activating STING and upregulating interferon-related genes.

This study identifies BRAF mutations in AML, showing poor outcomes and unique co-mutation patterns, suggesting potential targeted therapies.

This study shows that S1P receptor modulators resensitize NRAS-mutated FLT3-ITD AML cells to FLT3 inhibitors by inhibiting downstream signaling pathways.

The paper investigates how hypoxia and glutamine affect FLT3 inhibitor resistance in FLT3-ITD AML, finding that glutamine reduces FLT3-ITD expression.

The paper analyzes bone marrow microenvironment changes in HMA-resistant MDS patients treated with guadecitabine and atezolizumab, finding that long-term survivors show reduced immunosuppressive monocytes and expanded effector lymphocytes.